Crizocent is indicated for the treatment of patients based on genetic diagnostic confirmation of: 🔹 Metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. 🔹 Metastatic non-small cell lung cancer (NSCLC) that is ROS1-positive.

Dosage and administration

Sales Unit: 1 bottle containing 60 capsules, each containing 250 mg of Crizotinib. ⚠️ APPLICATION INSTRUCTIONS: Dosage: The standard recommended dose is 250 mg taken orally twice daily (total daily dose 500 mg). Method: Swallow capsules whole. May be taken with or without food. Dietary Restrictions: Avoid grapefruit and grapefruit juice during treatment, as they may increase the concentration of the drug in the blood. Storage: Store in a cool, dry place at a temperature not exceeding 30°C.

⛔ Organ Impairment: Severe renal or hepatic impairment requires strict medical supervision and possible dose adjustment. ⛔ Pregnancy: Known to cause fetal harm; use during pregnancy or breastfeeding is strictly prohibited. Hypersensitivity to Crizotinib or any of its excipients. Congenital long QT syndrome or concurrent use of drugs that prolong the QT interval.

Supervision by a healthcare professional experienced in oncology is required. Potential side effects include: 👁️ Vision: Visual disturbances (blurred vision, double vision, or photopsia), typically occurring early in treatment. 🤢 Gastrointestinal: Nausea, diarrhea, vomiting, and constipation. 🩸 Hepatobiliary: Elevated liver enzymes (ALT, AST) and neutropenia. 🏃♂️ General: Edema (swelling), fatigue, and dizziness.

Crizocent 250 — Crizotinib 250 mg, 60 product-page.units_short, Incepta Pharmaceuticals

100% original product

Active ingredient

Crizotinib

Manufacturer

Incepta Pharmaceuticals

Dosage 250 mg

Dosage form Capsules

Capsules per pack 60

Crizocent 250 Capsules — Crizotinib 250 mg (60 Capsules) Incepta

Name: Crizocent 250
Brand: Incepta Pharmaceuticals
SKU: PROD-250
Price: 14946 UAH
Availability: InStock

14946₴ ~~15858₴~~ -6%

Crizocent 250 mg (Crizotinib) is a highly selective targeted anticancer agent and an inhibitor of the ALK, ROS1, and MET receptor tyrosine kinases. The mechanism of action involves blocking signaling pathways responsible for the growth, survival, and proliferation of cancer cells in tumors with specific genetic rearrangements. Crizocent effectively inhibits disease progression and promotes tumor shrinkage in patients with appropriate biomarkers.

Manufacturer: Incepta Pharmaceuticals Ltd. This medicinal product is a high-quality generic of the innovator drug Xalkori. It is produced in state-of-the-art facilities compliant with international GMP standards, ensuring full bioequivalence and identical therapeutic efficacy to the brand-name drug at a more cost-effective price.

Key Features:

✅ Triple Inhibition: Potent activity against three major oncogenic drivers: ALK, ROS1, and c-MET.
✅ Proven Efficacy: Delivers robust clinical responses in patients with metastatic non-small cell lung cancer (NSCLC).
✅ Oral Administration: Capsule form allows for convenient outpatient treatment.

Crizocent is indicated for the treatment of patients based on genetic diagnostic confirmation of:

🔹 Metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive.
🔹 Metastatic non-small cell lung cancer (NSCLC) that is ROS1-positive.

Sales Unit: 1 bottle containing 60 capsules, each containing 250 mg of Crizotinib.

⚠️ APPLICATION INSTRUCTIONS:

Dosage: The standard recommended dose is 250 mg taken orally twice daily (total daily dose 500 mg).
Method: Swallow capsules whole. May be taken with or without food.
Dietary Restrictions: Avoid grapefruit and grapefruit juice during treatment, as they may increase the concentration of the drug in the blood.
Storage: Store in a cool, dry place at a temperature not exceeding 30°C.

⛔ Organ Impairment: Severe renal or hepatic impairment requires strict medical supervision and possible dose adjustment.
⛔ Pregnancy: Known to cause fetal harm; use during pregnancy or breastfeeding is strictly prohibited.
Hypersensitivity to Crizotinib or any of its excipients.
Congenital long QT syndrome or concurrent use of drugs that prolong the QT interval.

Supervision by a healthcare professional experienced in oncology is required. Potential side effects include:

👁️ Vision: Visual disturbances (blurred vision, double vision, or photopsia), typically occurring early in treatment.
🤢 Gastrointestinal: Nausea, diarrhea, vomiting, and constipation.
🩸 Hepatobiliary: Elevated liver enzymes (ALT, AST) and neutropenia.
🏃‍♂️ General: Edema (swelling), fatigue, and dizziness.